Risperidone controlled-release implant - Braeburn Pharmaceuticals

Drug Profile

Risperidone controlled-release implant - Braeburn Pharmaceuticals

Alternative Names: BB0817; EN 3342

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endo Pharmaceuticals
  • Developer Braeburn Pharmaceuticals
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Schizophrenia

Most Recent Events

  • 26 Apr 2017 Braeburn Pharmaceuticals announces intention to submit NDA to the US-FDA for Schizophrenia in December 2017
  • 26 Apr 2017 Adverse events, efficacy, pharmacokinetics data from a phase II trial in Schizophrenia released by Braeburn Pharmaceuticals
  • 01 Apr 2016 Phase-III clinical trials in Schizophrenia in USA (SC) (NCT02773576)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top